Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Rosen

Showing results (61-70 of 207) with videos related to

Pageof 21
Sort By:
Cancer Cell|January 11, 2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activitySarat Chandarlapaty, Ayana Sawai, Maurizio Scaltriti, et al.
Cancer Discovery|December 6, 2011
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signalingVanessa S Rodrik-Outmezguine, Sarat Chandarlapaty, Nen C Pagano, et al.
Nature Communications|February 11, 2021
Mutant-selective degradation by BRAF-targeting PROTACsShanique Alabi, Saul Jaime-Figueroa, Zhan Yao, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2008
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell linesRebecca Leboeuf, Jacqueline E Baumgartner, Miriam Benezra, et al.
Cancer Research|December 7, 2007
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibitionDavid B Solit, Elmer Santos, Christine A Pratilas, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2003
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumorsPaola de Candia, David B Solit, Dilip Giri, et al.
Plos One|August 30, 2008
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signalingQing-Bai She, Sarat Chandarlapaty, Qing Ye, et al.
Breast Cancer Research and Treatment|March 4, 2003
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002Christopher Benz, Gary Clark, Suzanne Conzen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancerSarat Chandarlapaty, Rita A Sakr, Dilip Giri, et al.
Nature Biotechnology|January 8, 2008
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivoErik Henke, Jonathan Perk, Jelena Vider, et al.
Pageof 21

Showing results (61-70 of 207) with videos related to

Sort By:
Pageof 21
Cancer Cell|January 11, 2011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activitySarat Chandarlapaty, Ayana Sawai, Maurizio Scaltriti, et al.
Cancer Discovery|December 6, 2011
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signalingVanessa S Rodrik-Outmezguine, Sarat Chandarlapaty, Nen C Pagano, et al.
Nature Communications|February 11, 2021
Mutant-selective degradation by BRAF-targeting PROTACsShanique Alabi, Saul Jaime-Figueroa, Zhan Yao, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2008
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell linesRebecca Leboeuf, Jacqueline E Baumgartner, Miriam Benezra, et al.
Cancer Research|December 7, 2007
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibitionDavid B Solit, Elmer Santos, Christine A Pratilas, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2003
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumorsPaola de Candia, David B Solit, Dilip Giri, et al.
Plos One|August 30, 2008
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signalingQing-Bai She, Sarat Chandarlapaty, Qing Ye, et al.
Breast Cancer Research and Treatment|March 4, 2003
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002Christopher Benz, Gary Clark, Suzanne Conzen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancerSarat Chandarlapaty, Rita A Sakr, Dilip Giri, et al.
Nature Biotechnology|January 8, 2008
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivoErik Henke, Jonathan Perk, Jelena Vider, et al.
Pageof 21